← Back
NeuroTrials.ai
Neurology Clinical Trial Database

PRESTIGE-AF

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

Year of Publication: 2025

Authors: Roland Veltkamp, Eleni Korompoki, Kirsten H Harvey, ..., Peter U Heuschmann

Journal: The Lancet

Citation: Lancet 2025; 405: 927–36

Link: https://doi.org/10.1016/S0140-6736(25)00333-2


Clinical Question

In survivors of intracerebral haemorrhage with atrial fibrillation, do DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage compared with no anticoagulation?

Bottom Line

DOACs dramatically reduce ischaemic stroke in ICH survivors with atrial fibrillation (HR 0.05), but this benefit is partly offset by a substantially increased risk of recurrent ICH (HR 10.89). Non-inferiority for recurrent ICH was not established. Composite endpoints and mortality trended in favour of DOACs but were not statistically conclusive.

Major Points

  • First completed phase 3 RCT of DOACs vs no anticoagulation in ICH survivors with atrial fibrillation
  • DOACs reduced first ischaemic stroke with HR 0.05 (95% CI 0.01–0.36; p<0.0001); ischaemic stroke rate was 0.83 vs 8.60 per 100 patient-years (NNT 13 per year)
  • Non-inferiority for recurrent ICH was NOT met: HR 10.89 (90% CI 1.95–60.72; p=0.96); ICH rate was 5.00 vs 0.82 per 100 patient-years (NNH 24 per year)
  • All stroke and systemic embolism composite favoured DOACs (event rate ratio 0.53, 95% CI 0.27–0.99)
  • Net clinical benefit composite (all stroke/SE, MI, CV mortality, major bleeding) trended towards DOACs (19.20 vs 26.52 per 100 patient-years; ratio 0.67, 95% CI 0.33–1.36)
  • Cardiovascular mortality point estimates favoured DOACs (2.92 vs 5.73 per 100 patient-years; HR 0.51, 95% CI 0.21–1.27)
  • Major bleeding was significantly higher with DOACs (8.75 vs 2.05 per 100 patient-years; ratio 4.27, 95% CI 1.74–12.80)
  • Recurrent ICH risk did not appear to differ by lobar vs non-lobar haematoma location, though events were too few for definitive conclusions
  • 85% of patients were anticoagulated prior to index ICH; median time from ICH to enrolment was 49 days
  • No patients were lost to follow-up; 10% crossover rate was lower than anticipated

Design

Study Type: Multicentre, open-label, randomised, phase 3 trial

Randomization: 1

Blinding: Open-label. Only the events adjudication committee was masked to treatment allocation, drug use, and participant identity via redaction of source documents. Patients, treating clinicians, and investigators were unmasked.

Enrollment Period: May 31, 2019 to November 30, 2023

Follow-up Duration: Median 1.4 years (IQR 0.7–2.3); minimum 6 months, up to 36 months

Centers: 75

Countries: UK, Germany, Austria, Spain, Italy, France

Sample Size: 319

Analysis: Intention-to-treat for primary analysis. Fixed sequence hierarchical testing for coprimary endpoints (ischaemic stroke tested first for superiority; recurrent ICH tested for non-inferiority only if first test significant). Log-rank test for time-to-first-event. Cox proportional hazards regression adjusted for ICH location, sex, and age. Per-protocol analysis required for non-inferiority confirmation. Sensitivity analyses included frailty models with random centre effect, risk-score imputation for informative censoring. Count data regression models for secondary endpoints. R version 4.4.1.


Inclusion Criteria

  • Age ≥18 years
  • Spontaneous intracerebral haemorrhage
  • Atrial fibrillation with an indication for anticoagulation
  • Modified Rankin Scale score ≤4
  • Enrolled 14 days to 12 months after index ICH

Exclusion Criteria

  • ICH resulting from vascular malformation or trauma
  • Presence of or plan to implant a left atrial appendage occlusion device

Arms

FieldDOAC groupControl
InterventionDirect oral anticoagulant (apixaban [54%], dabigatran [21%], edoxaban [18%], or rivaroxaban [6%]) at a dose licensed for stroke prevention in atrial fibrillation by the EMA, at the discretion of local investigatorsNo anticoagulation; antiplatelet therapy (e.g., aspirin 100 mg daily) in 33% or no antithrombotic treatment in 67%, at the discretion of local investigators. Dual antiplatelets not permitted at enrolment but allowed during follow-up if clinically warranted.
DurationMedian 1.4 years follow-upMedian 1.4 years follow-up

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Coprimary endpoints: (1) First incident ischaemic stroke (tested for superiority); (2) First recurrent intracerebral haemorrhage (tested for non-inferiority with margin HR <1.735)PrimaryIschaemic stroke: 20 events (8.60 per 100 patient-years); Recurrent ICH: 1 event (0.82 per 100 patient-years)Ischaemic stroke: 1 event (0.83 per 100 patient-years); Recurrent ICH: 11 events (5.00 per 100 patient-years)Ischaemic stroke: 0.05; Recurrent ICH: 10.89Ischaemic stroke: p<0.0001; Recurrent ICH: p=0.96 (non-inferiority NOT met)
All stroke and systemic embolismSecondary27 events; 11.06 per 100 patient-years14 events; 5.83 per 100 patient-years0.5395% CI 0.27–0.99
Net clinical benefit (all stroke/SE, MI, CV mortality, major bleeding)Secondary45 events; 26.52 per 100 patient-years32 events; 19.20 per 100 patient-years0.6795% CI 0.33–1.36
All-cause mortalitySecondary21 events; 8.60 per 100 patient-years16 events; 6.67 per 100 patient-years0.7895% CI 0.41–1.49
Cardiovascular mortalitySecondary14 events; 5.73 per 100 patient-years7 events; 2.92 per 100 patient-years0.5195% CI 0.21–1.27
Major adverse cardiac eventsSecondary15 events; 6.14 per 100 patient-years9 events; 3.75 per 100 patient-years0.6195% CI 0.27–1.40
Serious adverse eventsAdverse89 (55%)70 (44%)
DeathAdverse21 (13%)16 (10%)
Any major bleeding (ISTH)Adverse5 events; 2.05 per 100 patient-years21 events; 8.75 per 100 patient-years4.2795% CI 1.74–12.80
Any intracranial bleedingAdverse2 events; 0.82 per 100 patient-years15 events; 6.25 per 100 patient-years7.6395% CI 2.15–48.43

Subgroup Analysis

Formal subgroup analyses were not performed as only 1 ischaemic stroke event occurred in the DOAC group and 1 recurrent ICH event in the no anticoagulation group. Post-hoc analysis showed recurrent ICH risk did not appear to differ by lobar vs non-lobar haematoma location, but event numbers were too small for definitive conclusions. Differential risks by haematoma location were not identifiable.


Criticisms

  • Low number of primary outcome events and short follow-up (median 1.4 years) resulting in broad confidence intervals limiting interpretability
  • Open-label design — only the adjudication committee was masked, potentially introducing bias in reporting and management
  • Study was underpowered for secondary endpoints; trends in net benefit and mortality require confirmation in larger trials
  • Original target sample size was 654 but revised to ~312 due to slow recruitment (partly COVID-19 related), limiting statistical power
  • Exclusion of patients with severe disability (mRS >4), which may have enriched for patients with small haematoma volumes (median 3–4 mL), limiting generalisability
  • Predominantly White European population (>95%) limits generalisability to other ethnicities
  • Women were under-represented (35% of participants)
  • 10% crossover rate between groups, though lower than anticipated and per-protocol results were consistent
  • Slight imbalance in lobar ICH between groups (34% vs 26%) due to discrepancies between local and core imaging reads
  • Too few events to perform subgroup analyses or stratify by specific DOAC type
  • 11 patients underwent left atrial appendage closure during follow-up, potentially confounding results
  • Non-inferiority margin of HR <1.735 for recurrent ICH was generous and the trial still failed to meet it

Funding

European Commission as part of the Horizon 2020 research and innovation programme (grant 754517)

Based on: PRESTIGE-AF (The Lancet, 2025)

Authors: Roland Veltkamp, Eleni Korompoki, Kirsten H Harvey, ..., Peter U Heuschmann

Citation: Lancet 2025; 405: 927–36

Content summarized and formatted by NeuroTrials.ai.